Results 51 to 60 of about 9,972 (168)

Type 1 interferons as a potential treatment against COVID-19

, 2020
Elsevier Public Health emergency CollectionInternational audienceType 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV.
Sallard, Erwan, Lescure, François-Xavier, Mentré, France, Yazdanpanah, Yazdan, Peiffer-Smadja, Nathan   +4 more
core   +1 more source

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz, Neha V. Safi, Iliana Pliska‐Bloch, Ulrike W. Kaunzner, Ha Luu, Mert Sisman, Yi Wang, Thanh D. Nguyen, Sandra Hurtado Rúa, Susan A. Gauthier   +9 more
wiley   +1 more source

Interferons - A Review

, 2005
Interferons are a family of proteins and glycoproteins that have a variety of biologic actions. Interferons were first discovered in 1957 and several clinical trials have been conducted since then to unravel the action and clinical applications of ...
Shwetha Shetty, Karthikeya Patil, V G Mahima   +2 more
core  

Bunyamwera bunyavirus nonstructural protein NSs counteracts the induction of alpha/beta interferon

, 2002
Production of alpha/beta interferons (IFN-α/β) in response to viral infection is one of the main defense mechanisms of the innate immune system. Many viruses therefore encode factors that subvert the IFN system to enhance their virulence.
Richard E. Randall, Randall, Richard E, Friedemann Weber, Fazakerley, John K., Nina Kessler, Weber, F, Elliott, Richard M., Fazakerley, John K, Weber, Friedemann, Weber, F., Streitenfeld, Hein, Elliott, Richard M, Randall, R.E., Kessler, N, Elliott, R.M., Streitenfeld, H., Richard M. Elliott, Kessler, N., Anne Bridgen, Bridgen, A., Streitenfeld, H, Fazakerley, J.K., Kessler, Nina, Hein Streitenfeld, Bridgen, A, Elliott, Richard Michael, Fazakerley, JK, John K. Fazakerley, Bridgen, Anne, Randall, Richard Edward   +29 more
core   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Interferons

, 1992
LR: 20061107; PUBM: Print; JID: 7501160; 9008-11-1 (Interferons); 9035-51-2 (Cytochrome P-450 Enzyme System); CON: JAMA. 1991 Sep 11;266(10):1375-83.

core  

The New Alpha Interferons

, 1985
Alpha interferons are biological response modifiers that regulate immune function, slow cell proliferation, and inhibit virus replication. Large supplies of purified preparations are now available for clinical trials.
Donald C. McLeod, Carol McManus Balmer
core   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

Structural model for interferons

, 1985
Secondary structures of leucocyte α1- and α2-interferons and of fibroblast β-interferon are calculated using the molecular theory of protein secondary structures.
Ptitsyn, O.B., A.V. Finkelstein, A.G. Murzin, Murzin, A.G., O.B. Ptitsyn, Finkelstein, A.V.   +5 more
core   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source